SJS Investment Consulting’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.11K Hold
118
– – ﹤0.01% 2456
2026
Q2
$1.03K Buy
118
+108
+1,080% +$817 ﹤0.01% 2022
2026
Q1
$77 Sell
10
-54
-84% -$370 ﹤0.01% 2180
2025
Q4
$127 Buy
+64
New +$145 ﹤0.01% 1914
2025
Q2
– Sell
-9
Closed -$28 – 1598
2025
Q1
$28 Sell
9
-41
-82% -$124 ﹤0.01% 1583
2024
Q4
$128 Buy
50
+32
+178% +$133 ﹤0.01% 1503
2024
Q3
$67 Sell
18
-40
-69% -$185 ﹤0.01% 1599
2024
Q2
$367 Buy
58
+47
+427% +$310 ﹤0.01% 1387
2024
Q1
$60 Buy
+11
New +$50 ﹤0.01% 1601
2023
Q2
– Sell
-3
Closed -$6 – 1611
2023
Q1
$6 Sell
3
-1
-25% -$3 ﹤0.01% 1576
2022
Q4
$20 Buy
+4
New +$22 ﹤0.01% 1580
2022
Q1
$0 Buy
+1
New +$6 ﹤0.01% 1000

Other funds holding IBRX

SJS Investment Consulting's IBRX Position: Q3 2026 in Review

SJS Investment Consulting held its ImmunityBio (IBRX) position steady in Q3 2026 at 118 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

SJS Investment Consulting first reported a position in IBRX in Q1 2022 and has held it in 12 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • SJS Investment Consulting held 118 shares of ImmunityBio worth $1.11K as of Q3 2026.
  • SJS Investment Consulting left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2456 holding.
  • SJS Investment Consulting first reported a position in ImmunityBio in Q1 2022 and has held it in 12 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.